Caribou Biosciences, Inc. announced a strategic shift focusing on its lead oncology programs, CB-010 and CB-011, involving workforce and cost reductions aimed at extending its cash runway into the ...
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to ...
-- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 ...
BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...
Tsukuba, Japan—The human genome contains approximately 1,600 types of transcription factors responsible for regulating gene activity across more than 400 tissue and cell types. Chromatin ...
Hosted on MSN
Pfizer targets $7.7B in operational efficiency savings by 2027, highlights strategic R&D shifts
CEO Dr. Albert Bourla discussed Pfizer's strategic focus on improving R&D productivity, emphasizing a disciplined approach to advancing its pipeline. The company highlighted the discontinuation of ...
If you’ve ever sat through a death-by-PowerPoint strategy presentation, you know the pain. Most leadership teams go too deep with their strategic plans. Traditional plans are bloated. They’re loaded ...
The human genome contains approximately 1,600 types of transcription factors responsible for regulating gene activity across more than 400 tissue and cell types. Chromatin immunoprecipitation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback